← Eichor
Condition: Epidermolysis Bullosa Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Epidermolysis Bullosa

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
Phase N/A · 1 location(s) · Stanford University · NCT01019148Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
Phase 2 · 2 location(s) · Stanford University · NCT06731933A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)
Phase N/A · 1 location(s) · Krystal Biotech, Inc. · NCT06563414A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
Phase N/A · 5 location(s) · Amryt Pharma · NCT06423573Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders
EARLY_Phase 1 · 1 location(s) · Northwestern University · NCT05649098A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dys
Phase N/A · 4 location(s) · Abeona Therapeutics, Inc · NCT07700966FARD (RaDiCo Cohort) (RaDiCo-FARD)
Phase N/A · 15 location(s) · Institut National de la Santé Et de la Recherche Médicale, F · NCT05954416A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genode
Phase 2 · 2 location(s) · Centre Hospitalier Universitaire de Nice · NCT06136403Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa
Phase 1/Phase 2 · 1 location(s) · Isfahan University of Medical Sciences · NCT07230223Gentamicin for Junctional Epidermolysis Bullosa
Phase 1/Phase 2 · 1 location(s) · University of Southern California · NCT03526159Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling
Phase N/A · 1 location(s) · Maastricht University Medical Center · NCT06330350Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa
Phase 3 · 1 location(s) · Paradigm Therapeutics · NCT07482787A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
Phase 3 · 5 location(s) · Krystal Biotech, Inc. · NCT07016750Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
Phase 1/Phase 2 · 1 location(s) · M. Peter Marinkovich · NCT06834035A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized
Phase 2 · 4 location(s) · Centre Hospitalier Universitaire de Nice · NCT06509984A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study
Phase 2 · 9 location(s) · Xinnate AB · NCT06594393A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis
Phase 2 · 2 location(s) · BioMendics, LLC · NCT07027345GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment
Phase 1/Phase 2 · 1 location(s) · CHU de Quebec-Universite Laval · NCT07193134MSC EVs in Dystrophic Epidermolysis Bullosa
Phase 1/Phase 2 · 3 location(s) · Aegle Therapeutics · NCT04173650Multicenter, Randomized, Non-inferiority Study to Compare the Performance and Safety of Debrisoft® Duo With Debrisoft® P
NA · 5 location(s) · Lohmann & Rauscher · NCT07312513Long-Term Follow-up Protocol
Phase N/A · 3 location(s) · Krystal Biotech, Inc. · NCT04917887Study of the Blood and Skin Immunological Profile of Patients With Recessive Dystrophic Epidermolysis Bullosa: in Vivo A
Phase N/A · 2 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06177353A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
Phase 3 · 6 location(s) · Chiesi Farmaceutici S.p.A. · NCT06917690
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.